INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)

NCT07417618 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing whether certain diabetes medications can help prevent heart attacks, strokes, or death in adults with type 2 diabetes and heart disease or those who are overweight.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Type Observational

Participants 60,000 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2026-01 · est. completion 2026-05

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT07417618 ↗

Description as written by the study sponsor.

Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.

Treatments tested

Dulaglutide Drug

Initiation of dulaglutide dispensing claim is used as the exposure.
Semaglutide Drug

Initiation of semaglutide dispensing claim is used as the exposure.
Tirzepatide Drug

Initiation of tirzepatide dispensing claim is used as the exposure.
Sitagliptin Drug

Initiation of sitagliptin dispensing claim is used as the reference.

Main thing measured	Composite of myocardial infarction, stroke, or all-cause mortality (with ASCVD)
Sponsor	Brigham and Women's Hospital
Conditions studied	Type 2 Diabetes, Overweight, ASCVD
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07417618 ↗